Diagnosis and treatment of pediatric osteoporosis
- PMID: 25232753
- DOI: 10.1097/MED.0000000000000106
Diagnosis and treatment of pediatric osteoporosis
Abstract
Purpose of review: Progress toward identifying and treating disorders of bone fragility in pediatric patients has been considerable in recent years. This article will summarize several key advances in the management of osteoporosis in children and adolescents.
Recent findings: Recommendations from the 2013 pediatric Position Development Conference provide expert guidance for evaluating bone health in younger patients. The diagnosis of pediatric osteoporosis can be made in a child with low-trauma vertebral fractures or a combination of low bone mass and long bone fractures. Management of bone fragility includes optimizing nutrition, activity, and treatment of the underlying disease. Pharmacologic agents can be considered if these measures fail to prevent further bone loss or fractures. Although the efficacy and safety of several intravenous and oral bisphosphonates have been examined, there is still no consensus on the optimal drug, dose, or duration of treatment. Observational studies of children with secondary osteoporosis provide insight into risk factors for fracture or the potential for recovery.
Summary: Despite advances in the diagnosis and treatment of pediatric osteoporosis, more research is needed. Randomized controlled trials of pharmacologic agents should be defined to target those identified at the highest risk by observational studies.
Video abstract: http://links.lww.com/COE/A9
Similar articles
-
Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.Curr Osteoporos Rep. 2017 Aug;15(4):271-282. doi: 10.1007/s11914-017-0371-2. Curr Osteoporos Rep. 2017. PMID: 28620868 Review.
-
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ. 2002 Nov 12;167(10 Suppl):S1-34. CMAJ. 2002. PMID: 12427685 Free PMC article. Review.
-
ENDOCRINOLOGY AND ADOLESCENCE: Osteoporosis in children: diagnosis and management.Eur J Endocrinol. 2015 Dec;173(6):R185-97. doi: 10.1530/EJE-14-0865. Epub 2015 Jun 3. Eur J Endocrinol. 2015. PMID: 26041077 Review.
-
Screening for osteoporosis.Am Fam Physician. 2011 May 15;83(10):1201-2. Am Fam Physician. 2011. PMID: 21568255 No abstract available.
-
[Update on current care guidelines: osteoporosis].Duodecim. 2014;130(14):1466-8. Duodecim. 2014. PMID: 25158587 Review. Finnish.
Cited by
-
GLUCOCORTICOID-INDUCED BONE DISEASE: MECHANISMS AND IMPORTANCE IN PEDIATRIC PRACTICE.Rev Paul Pediatr. 2017 Apr-Jun;35(2):207-215. doi: 10.1590/1984-0462;2017/;35;2;00007. Epub 2017 May 29. Rev Paul Pediatr. 2017. PMID: 28977339 Free PMC article. Review.
-
Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility.J Clin Endocrinol Metab. 2025 Jun 17;110(7):2031-2040. doi: 10.1210/clinem/dgae661. J Clin Endocrinol Metab. 2025. PMID: 39324646
-
The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy.Int J Pediatr Endocrinol. 2019;2019:4. doi: 10.1186/s13633-019-0070-0. Epub 2019 Dec 23. Int J Pediatr Endocrinol. 2019. PMID: 31889957 Free PMC article.
-
Non-osteogenic muscle hypertrophy in children with McArdle disease.J Inherit Metab Dis. 2018 Nov;41(6):1037-1042. doi: 10.1007/s10545-018-0170-7. Epub 2018 Mar 28. J Inherit Metab Dis. 2018. PMID: 29594644
-
Advances in the Interdisciplinary Care of Children with Klinefelter Syndrome.Adv Pediatr. 2016 Aug;63(1):15-46. doi: 10.1016/j.yapd.2016.04.020. Adv Pediatr. 2016. PMID: 27426894 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials